The specter of generic rivalry has consistently loomed above copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the prospects of related drug stakes. While early years saw significant returns, the patent expiration has opened the way for cheaper copies, possibly reducing revenue and posing a significant danger for stakeholde